Does Eliem Therapeutics (USA Stocks:ELYM) have steady basic indicators based on the new hike?

ELYM Stock  USD 3.85  0.23  6.35%   
The stock continues to experience above-average trading activities. While some of us are excited about healthcare space, let's try to summarize Eliem Therapeutics in greater detail to make a better evaluation of its fundamental indicators. We will look into reasons why it is still very possible for the company to generate above-average returns. We currently estimate Eliem Therapeutics as undervalued. The real value is approaching 10.87 per share.
Published over three weeks ago
View all stories for Eliem Therapeutics | View All Stories
We provide trade advice to complement the prevailing expert consensus on Eliem Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Eliem Therapeutics income statement, its balance sheet, and the statement of cash flows. Potential Eliem Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Eliem Therapeutics investors may use each financial statement separately, they are all related. The changes in Eliem Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eliem Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Eliem Therapeutics fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Eliem Therapeutics performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Eliem Therapeutics shares is the value that is considered the true value of the share. If the intrinsic value of Eliem is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Eliem Therapeutics.
Please read more on our fundamental analysis page.

How important is Eliem Therapeutics's Liquidity

Eliem Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Eliem Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Eliem Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Eliem Therapeutics's total debt and its cash.

How does Eliem utilize its cash?

To perform a cash flow analysis of Eliem Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Eliem Therapeutics is receiving and how much cash it distributes out in a given period. The Eliem Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.


Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Eliem Therapeutics is not uncomon. Institutional investors typically avoid acquiring a high percentage of Eliem Therapeutics stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Eliem is distributed among investors.

Ownership Allocation

Eliem Therapeutics holds a total of twenty-six million five hundred sixty-seven thousand seven hundred outstanding shares. Over half of Eliem Therapeutics outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Eliem Therapeutics. Please watch out for any change in the institutional holdings of Eliem Therapeutics as this could mean something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Retail Investors4.58

Eliem Therapeutics implied volatility may change after the hike

New Information Ratio is up to 0.03. Price may pull down again. Eliem Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Eliem Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Eliem Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Eliem Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Eliem Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Conclusion on Eliem Therapeutics

While some other firms within the biotechnology industry are still a little expensive, even after the recent corrections, Eliem Therapeutics may offer a potential longer-term growth to stakeholders. To summarize, as of the 31st of December 2022, our analysis shows that Eliem Therapeutics moves indifferently to market moves. The company is undervalued and projects low chance of financial distress for the next 2 years. However, our overall 90 days buy-or-sell advice on the company is Strong Sell.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Eliem Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to